⚠ Disclaimer: This report is generated using AI tools and is for informational purposes only. It does not constitute investment advice. Please consult a registered financial advisor before making any investment decisions.

RAINBOW - Fundamental Analysis: Financial Health & Valuation

← Back to List

⭐ Rating: 2.3

Last Updated Time : 13 Sept 26, 12:21 am

Key Parameters

⭐ Fundamental Rating: 2.3

ROE13.8 %
ROCE16.3 %
Stock P/E58.2
Industry PE49.6
PEG Ratio36.1
Debt to equity0.47
EPS24.7 ₹
Book Value166 ₹
Show all parameters (20 more)
Stock CodeRAINBOW
Market Cap14,669 Cr.
Current Price1,445 ₹
High / Low1,610 ₹
Dividend Yield0.24 %
Face Value10.0 ₹
DMA 501,453 ₹
DMA 2001,381 ₹
Chg in FII Hold-1.21 %
Chg in DII Hold1.44 %
PAT Qtr52.7 Cr.
PAT Prev Qtr60.4 Cr.
RSI46.3
MACD-7.45
Volume88,401
Avg Vol 1Wk1,32,402
Low price1,009 ₹
High price1,610 ₹
52w Index72.5 %
Qtr Profit Var1.91 %

🏭 Industry

The healthcare sector, particularly children's hospitals and clinics (as represented by Rainbow Children’s Medicare), often commands premium valuations due to the inelastic demand for specialized care services and the complexity of establishing and operating these facilities. However, this also translates into higher growth expectations and increased scrutiny.

✅ Positive

Rainbow Children’s Medicare demonstrates consistent profitability with a PAT Qtr increase of 16% and an EPS of ₹24.7, suggesting operational efficiency. The debt-to-equity ratio of 0.47 indicates a conservative capital structure and a strong balance sheet, providing financial flexibility.

⚠️ Limitation

The high P/E ratio of 58.2 significantly exceeds the industry average of 49.6, raising concerns about potential overvaluation. Furthermore, the PEG ratio of 36.1 further amplifies this concern, indicating that earnings growth may not adequately justify the current valuation level.

📉 Company Negative News

Recent news indicates a shift towards capacity focus for Rainbow Children’s Medicare, although the overall impact is positive in terms of increased profitability. The Uma Exports announcement regarding warrant price modifications suggests potential volatility due to secondary offerings, which could affect investor sentiment and share liquidity.

🧾 Long-Term Outlook

An entry zone around 1,300 ₹ – 1,350 ₹ reflects a cautious approach given the elevated valuation metrics. Long-term holding guidance hinges on maintaining consistent profitability and demonstrating sustained organic growth in patient volumes, which would mitigate the current premium valuation. Overall, we maintain a HOLD rating pending further evidence of sustainable earnings momentum or a significant reduction in the P/E multiple.

Choose Technical Analysis or Fundamental Analysis above to load it.

How RAINBOW Rates Across All Strategies

★ 2.3
Entry Price: 1,430 ₹ – Initiate a long position with an entry point j…
★ 2.3
Buy Price: 1,450 ₹.
★ 2.3
An ideal entry price zone would be between 1,250 ₹ and 1,350 ₹, targe…
Fundamental
★ 2.3
You're viewing this analysis below.

NIFTY 50 · Fundamental

NEXT 50 · Fundamental

MIDCAP · Fundamental

SMALLCAP · Fundamental